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The Mydriatic Effect of Tropicamide and its Diagnostic Use in
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The mydriatic effect of topically administered tropicamide was investigated as a possible diagnostic
indicator for Alzheimer’s disease. Although an initial series seemed to show a correlation between
hypersensitivity to tropicamide and intellectual impairment, subsequent testing showed a greater
inter- and intra-individual variation than that between the normal group and the group of patients
with intellectual impairment. This procedure seems, therefore, to lack sufficient specificity to be
useful for such a diagnostic purpose. Copyright @ 1996 Elsevier Science Ltd
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INTRODUCTION
Sacks and Smith (1989) have” found a mydriatic
hypersensitivity to 0.01% topically administered tropi-
camide in patients with Down’s syndrome, which was
attributed to acetylcholinedeficiency.Scintoet al. (1994)
have reported such a procedure as a simple diagnostic
method for the differential diagnosis of Alzheimer’s
disease from others causing intellectual impairment.
In this paper, the authors have sought to eliminate all
other possible causes of variation in pupillary dilation.
Firstly, the effects of agitation, distress, unknown
systemicpharmaceuticals,and undetectedenvironmental
adaptati,pneffects were eliminated by measuring both
pupillary diameters, but administering tropicamide to
only one eye. All patients were given a Schirmer’s test,
tear film break up test, Meibomian gland evaluation,
endothelial cell count, corneal pachymetry, intra-ocular
pressure measurement and iris colour recorded.
The test was repeated after 4 weeks to assess the
reproducibilityof results over time, and an effect due to
corneal permeability was eliminated by comparing the
effect of tropicamideafter oxybuprocainpretreatmenton
either eye alternately of three control individuals [see
Fig. 6(A, B)].
SUBJECTSAND METHODS
34 intellectually impaired patients (age 69 i 11)
years, 20 male 14 female) were investigated.The onset
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of impairment varied from 2 to 5 years before the
experiment. Full neurological examinations including
cognitive tests, magnetic resonance imaging, X-ray
computed tomography, electro-encephalography,
Doppler ultrasonography and blood chemistry were
carried out. Only those patients fulfilling the NINCDS–
ADRDA criteria (Tierney et al., 1988)were confirmedas
having Alzheimer’s disease; these were 23 in number.
This left 11 individuals with impairment but not firm
diagnosisof Alzheimer’s disease.
Thirty-one normal individuals (age 54.6 + 14.2, 13
male, 18 female) with no intellectual impairment were
used as a control group.
Prior to the test each individualunderwent a standard
ophthalmic workup (visual acuity, biomicroscopic ex-
amination including the fundus). The test included
tonometry, endothelialmicroscopy,corneal pachymetry,
Meibomiangland evaluation,tear filmbreak-up time and
Schirmer’s test.
The main part of the test comprised infrared pupillo-
graphy as describedby Schaeffelet al. (1993),based on a
personal computer receiving data from an infra red
sensitive camera (Canon) via an Oculus-OC-300/
512 x 1024 frame grabber. This recorded the following
at a rate of 25 Hz (real time): vertical and horizontal eye
movement, accommodation by on-line retinoscopy and
pupillary size. Background illuminance was 100 IUX,
spatial resolutionwas 0.1 mm.
Data registrationis halted during blinking for approxi-
mately 1.5 sec to avoid pupil changes. The automated
data collection is expressed as the, average of 250
measurementscalculated off-line.These on-line controls
seem to be necessary to obtain reliable results. After
baseline pupil measurement, 0.01% tropicamide was
administeredto one eye chosen at random and pupillary
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TABLE 1. Tear film and comeal parameters of our 34 intellectually
impaired patients
OD 0s Units
Schirmer 13.3 ~ 12.3 14.3 * 12 mm
Break up t. 7.0 * 3 7.8 & 4.2 sec
Meibom 1.2 * 0.7 1.3 f 0.7 staging
Endothelialcells 2323 ~ 346 2332 ~ 330 clmmz
Pachymetry 523 ~ 37 524 ~ 36 P
All results are within the normal range for elderly individuals.
Furthermore, they were not different in the two separate patients
groups. n = 34.
measurementswere taken of both eyes at 15min intervals
for 90 min. After an interval of 4 weeks, the tests were
repeated in the same way but with both eyesbeing treated
with tropicamide in order to evaluate intra-individual
variation.
Written informed consent was obtained from patients
and care-givers, respectively.
STATISTICALANALYSIS
Comparing location (mean) and scale (variance)
parametrically we used the paired Student’s t-test after
comparing variances with Fisher’s F-test. With the
calculation of the Pearson’s r product–moment linear
correlation coefficient as well as with explorative data
analysis we tested the strength of association between
tear film parameters, corneal parameters, mind scores,
and the dilatoryeffect of tropicamide.In order to evaluate
whether the change in pupil diameter is associatedwith
comeal and tear film variables, the multiple correlation
coefficientwas calculated.
RESULTS
Tear film and corneal parameters were all within the
normal range for elderly individuals (Table 1). Further-
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FIGURE 1. Pupil dilation response to topically applied 0.01%
tropicamide in 34 intellectually impaired patients. Infrared pupillo-
graphymeasurementswere taken in 15min intervalsover the courseof
90 min. Maximumeffect over baseline is reached after 45 min.
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FIGURE2. Average dilationeffect of 0.01’%tropicamideafter 45 min
in intellectually impairedpatients. There is little change in the average
after 4 weeks (second visit) and no average difference in the fellow
eyes.
more, they were not different in the two separate groups
of patients. Neither single correlation nor multi-variant
analysis showed a correlation of pupil dilation with any
of the measured ocular anatomy or physiology.
For the intellectually impaired patients, Fig. 1 shows
an average YO change in pupil diameter 45 min after
tropicamide application of 18.6 t 11.02%. Figure 2
shows that there was little change in the average on the
secondvisit and no averagedifference in the fellow eyes,
however, Fig. 3 shows a striking intra-individual
variation. Individualresults could show a variation by a
factor of 2 between the first and second test in the same
eye. Figure 4 compares the results from the two separate
groups of those 23 patients confidently diagnosed with
AD to those 11less impaired.On the firstoccasiona clear
difference was seen (1’= 0.05; not shown in Fig. 4),
however, on the second test there was no significant
difference.
For the normal controls Fig. 5 shows an extreme
variation in the dilation effect. Figures as high as 6070
40 I patientagroup
FIGURE3. Strikingintra-individualvariation in the responseto 0.01%
tropicamide in cognitivelydeprived patients; pupillographymeasure-
ments were repeated under standardized conditions 4 weeks later
(second visit).
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Normals MMSE = 30 MMSE <30
FIGURE4. The averageresponseto 0.01%tropicamideafter 45 min is
not significantly different between normals, cognitively deprived
patients (MMSE= 30), and Alzheimer patients (MMSEc 30); MMSE
= Mini Mental State Examination.
and below 10% were found. Of the control individuals
with a dilation of more than 20’%on the first test, eight
had values below 10% and three individualsbetween 15
and 2090when tested 4 weeks later.
However, a clear-cut influenceof corneal permeability
on the response to tropicamide administrationcould be
demonstratedexperimentally:prior to tropicamideappli-
cation healthy controls (n = 3, 37 f 2 yr) received
anesthetic eye drops (oxybuprocain 0.4%) three times
in 2 min intervals in one eye. Figure 6(A) shows a 5090
pupil dilation over baseline in such pretreated eyes
compared to a discrete dilation of less than 10Yoin the
fellow eye. The nonspecific dilating effect due to
pretreatment could be verified by repeating the experi-
ments for the other eye [Fig. 6(B)].
DISCUSSION
In the patient collectivewe found an averagemydriatic
effect in the tropicamidetreated eye of 18.6%-similar to
the results obtained by Scinto-and no change in the
n
healthy controls (selected cases)
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FIGURE 5. Response to 0.01% tropicamide eye drops in healthy
controls (mean 12.6$%t 4.5; n = 31). Atter 45 min dilation effects
range between 7 and 57~0. Selected cases are shown.
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FIGURE 6. The influence of corneal permeability on the response to
0.01% tropicamide eye drops is shown. Prior to tropicamide
applicationto both eyes three healthy controls received oxybuprocain
eye drops in one eye. Subsequently, infra-red pupillography was
performed as described. In such pretreated eyes up to 5070dilation
over baseline was observed(A). The nonspecificdilating effect due to
pretreatment was verified by repeating the experiments for the other
eye (B).
average diameter of the untreated eye. The same
results—as regards the average mydriatic effect—were
obtained in a second test series performed 4 weeks later.
No differencewas seenbetween the right and the left eye.
Those patients complaining about memory impairment
although passing the MMSE showed less dilating
response in the first test series. However, on retesting,
this finding could not be reproduced; indicating that at
thispointpupillaryresponseto pharmacologicalagents is
not able to distinguish diagnosed AD patients from
patients complaining about memory impairment but
lacking clinically notable cognitive defects.
Despite the fact that pupillography was performed
under standardizedconditions, intra-individualvariation
in all subgroupsof patients as well as in control subjects
was extremelyhigh, indicatingthat this test is not specific
enough. Taking 13Y0of pupil dilation as a cut-off value
we would have missed 39?Z0of diagnosed AD patients,
while 67Y0of normal controls would have reacted false
positive.
Although the influence on corneal permeability of
oxybuprocain [see Fig. 6(A, B)] altered the effect of
tropicamide, no ocular pathologies were found in the
subjects tested to account for the large variability in
results found between individuals or occasions. Never-
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theless, the influence of epithelial barrier function and
endothelialpump function needs further attention.
All measurements of tear film condition are still
imprecise, however, Down’s syndrome patients appear
(Shapiro & France, 1985) to have anatomical anomalies
in the anterior segment (e.g. iris stromal atrophy,
keratoconus, blepharitis, nasolacrimal duct obstruction
etc.) which may cause a difference in the effect of
tropicamide.
The expected differentiationof intellectuallyimpaired
from normal individualsdue to a cholinergicdeficitwas
not found using this testing method. Further experimen-
tation with alternativepharmaceuticalagents or a testing
regime carried out over different time intervalswill have
to be conducted before the utility of this simple test of
pupillary reaction in the diagnosis of Alzheimer’s
desease can be determined.
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